Detalles de la búsqueda
1.
The role of multidisciplinary MS care teams in supporting lifestyle behaviour changes to optimise brain health among people living with MS: A qualitative exploration of clinician perspectives.
Health Expect
; 27(2): e14042, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38576113
2.
Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool.
Mult Scler J Exp Transl Clin
; 8(3): 20552173221124023, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36105273
3.
High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients.
Ther Adv Neurol Disord
; 14: 1756286421998915, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33948117
4.
Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS.
Neurol Clin Pract
; 10(6): 510-519, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33510947
5.
Multiple sclerosis risk variants regulate gene expression in innate and adaptive immune cells.
Life Sci Alliance
; 3(7)2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32518073
6.
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.
Mult Scler Relat Disord
; 19: 105-108, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29182993
7.
Association of plasma levels of Protein S with disease severity in multiple sclerosis.
Mult Scler J Exp Transl Clin
; 1: 2055217315596532, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-28607700
8.
Fingolimod after natalizumab and the risk of short-term relapse.
Neurology
; 82(14): 1204-11, 2014 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24610329
9.
Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)].
Mult Scler Relat Disord
; 22: 166, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29807821
Resultados
1 -
9
de 9
1
Próxima >
>>